The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Oxindole: A chemical prism carrying plethora of therapeutic benefits
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Leishmaniasis Worldwide and Global Estimates of Its Incidence
Alvar, J., Vélez, I. D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., Boer, M. D., & the WHO Leishmaniasis Control Team (2012) · PLoS ONE · doi:10.1371/journal.pone.0035671 · Cited by 5,141
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Molecular Characterization of the Human β 3 -Adrenergic Receptor
Emorine, L. J., Marullo, S., Briend-Sutren, M.-M., Patey, G., Tate, K., Delavier-Klutchko, C., & Strosberg, A. D. (1989) · Science · doi:10.1126/science.2570461 · Cited by 1,088
SHP-2 Tyrosine Phosphatase as an Intracellular Target of Helicobacter pylori CagA Protein
Higashi, H., Tsutsumi, R., Muto, S., Sugiyama, T., Azuma, T., Asaka, M., & Hatakeyama, M. (2002) · Science · doi:10.1126/science.1067147 · Cited by 1,029
Genin, M. J., Allwine, D. A., Anderson, D. J., Barbachyn, M. R., Emmert, D. E., Garmon, S. A., Graber, D. R., Grega, K. C., Hester, J. B., Hutchinson, D. K., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990373e · Cited by 729
Goodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 501
Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G., & Tang, C. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980123i · Cited by 489
NMDA receptor pathways as drug targets
Kemp, J. A., & McKernan, R. M. (2002) · Nature Neuroscience · doi:10.1038/nn936 · Cited by 476
London, C. A., Malpas, P. B., Wood-Follis, S. L., Boucher, J. F., Rusk, A. W., Rosenberg, M. P., Henry, C. J., Mitchener, K. L., Klein, M. K., Hintermeister, J. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1860 · Cited by 424
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Roskoski, R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.156 · Cited by 412
Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection
Singh, M., Kaur, M., Kukreja, H., Chugh, R., Silakari, O., & Singh, D. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.050 · Cited by 364
The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
Dance, M., Montagner, A., Salles, J.-P., Yart, A., & Raynal, P. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2007.10.002 · Cited by 361
Jiang, T., Kuhen, K., Wolff, K. C., Yin, H., Bieza, K., Caldwell, J. S., Bursulaya, B. D., Wu, T. Y., & He, Y. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.01.073 · Cited by 301
The role of Shp2 (PTPN11) in cancer
Mohi, M. G., & Neel, B. G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.011 · Cited by 274
Bramson, H. N., Corona, J., Davis, S. T., Dickerson, S. H., Edelstein, M., Frye, S. V., Gampe, R. T., Harris, P. A., Hassell, A., Holmes, W. D., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010117d · Cited by 269
Meyer-ter-Vehn, T., Covacci, A., Kist, M., & Pahl, H. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000959200 · Cited by 249
BROWN ADIPOSE TISSUE, β3-ADRENERGIC RECEPTORS, AND OBESITY
Lowell, M., & Flier, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.307 · Cited by 237
The discovery of potent cRaf1 kinase inhibitors
Lackey, K., Cory, M., Davis, R., Frye, S. V., Harris, P. A., Hunter, R. N., Jung, D. K., McDonald, O. B., McNutt, R. W., Peel, M. R., et al. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00668-x · Cited by 206
Linton, E. C., & Kozlowski, M. C. (2008) · Journal of the American Chemical Society · doi:10.1021/ja807026z · Cited by 198
Enantioselective Synthesis of 3,3-Disubstituted Oxindoles through Pd-Catalyzed Cyanoamidation
Yasui, Y., Kamisaki, H., & Takemoto, Y. (2008) · Organic Letters · doi:10.1021/ol801168j · Cited by 197
Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action
Williams, K. L. (2001) · Current Drug Targets · doi:10.2174/1389450013348489 · Cited by 168
EXPRESSION AND POSSIBLE FUNCTIONAL ROLE OF THE beta 3-ADRENOCEPTOR IN HUMAN AND RAT DETRUSOR MUSCLE
FUJIMURA, T., TAMURA, K., TSUTSUMI, T., YAMAMOTO, T., NAKAMURA, K., KOIBUCHI, Y., KOBAYASHI, M., & YAMAGUCHI, O. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61994-3 · Cited by 166
Chenard, B. L., Shalaby, I. A., Koe, B. K., Ronau, R. T., Butler, T. W., Prochniak, M. A., Schmidt, A. W., & Fox, C. B. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00114a018 · Cited by 143
Ali, M. A., Ismail, R., Choon, T. S., Yeong, K. Y., Wei, A. C., Pandian, S., Kumar, R. S., Osman, H., & Elumalai, M. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.108 · Cited by 142
Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles
Wood, E. R., Kuyper, L. F., Petrov, K. G., Hunter, R., Harris, P. A., & Lackey, K. E. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.12.002 · Cited by 137
Manley, P. W., Bold, G., Brüggen, J., Fendrich, G., Furet, P., Mestan, J., Schnell, C., Stolz, B., Meyer, T., Meyhack, B., et al. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.010 · Cited by 136
VanDongen, A. M. J. (2008) · CRC Press eBooks · doi:10.1201/9781420044157 · Cited by 128
Paira, P., Hazra, A., Kumar, S., Paira, R., Sahu, K. B., Naskar, S., Saha, P., Mondal, S., Maity, A., Banerjee, S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.049 · Cited by 118
Kia, Y., Osman, H., Kumar, R. S., Murugaiyah, V., Basiri, A., Perumal, S., Wahab, H. A., & Bing, C. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.01.066 · Cited by 104
Synthesis of oxindolesvia visible light photoredox catalysis
Ju, X., Liang, Y., Jia, P., Li, W., & Yu, W. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob06652h · Cited by 102
Lawrence, H. R., Pireddu, R., Chen, L., Luo, Y., Sung, S., Szymanski, A. M., Yip, M. L. R., Guida, W. C., Sebti, S. M., Wu, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002526 · Cited by 100
The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation
Ingrand, S. S., Barrier, L., Lafay‐Chebassier, C., Fauconneau, B., Page, G., & Hugon, J. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.08.022 · Cited by 93
Synthesis and anticancer activity of oxindole derived imidazo[1,5-a]pyrazines
Kamal, Ä., Ramakrishna, G., Raju, P. V. K., Rao, A., Viswanath, A., Nayak, V., & Sistla, R. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.027 · Cited by 86
Oxindole as starting material in organic synthesis
Ziarani, G. M., Gholamzadeh, P., Lashgari, N., et al. (2013) · ARKIVOC · doi:10.3998/ark.5550190.p008.074 · Cited by 78
Synthesis of 2-Oxindole Derivatives via the Intramolecular Heck Reaction on Solid Support
Arumugam, V., Routledge, A., Abell, C., & Balasubramanian, S. (1997) · Tetrahedron Letters · doi:10.1016/s0040-4039(97)01481-0 · Cited by 77
Potent small molecule inhibitors of spleen tyrosine kinase (Syk)
Lai, J. Y. Q., Cox, P. J., Patel, R., Sadiq, S., Aldous, D., Thurairatnam, S., Smith, K. J., Wheeler, D., Jagpal, S., Parveen, S., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00658-9 · Cited by 77
New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles
Fensome, A., Bender, R. H. W., Cohen, J. D., Collins, M. A., Mackner, V. A., Miller, L. L., Ullrich, J. W., Winneker, R. C., Wrobel, J. E., Zhang, P., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00746-1 · Cited by 75
Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents
Ribeiro, C. J. A., Amaral, J. D., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.048 · Cited by 67
Dreifuss, A. A., Bastos-Pereira, A. L., Ávila, T. V., Soley, B. D. S., Rivero, A. J., Aguilar, J. L., & Acco, A. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.04.029 · Cited by 67
Yu, L.-F., Li, Y., Su, M., Zhang, M., Zhang, W., Zhang, L.-N., Pang, T., Zhang, R., Liu, B., Li, J.-Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400028q · Cited by 66
Synthesis of novel 3′-spirocyclic-oxindole derivatives and assessment of their cytostatic activities
Yong, S. R., Ung, A. T., Pyne, S. G., Skelton, B. W., & WHITE, A. H. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.04.028 · Cited by 65
Moreau, J., Pieri, L., & Prud'hon, B. (1989) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1989.tb14637.x · Cited by 59
Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors
Ivanenkov, Y. A., Vasilevski, S. V., Beloglazkina, E. K., Kukushkin, M. E., Machulkin, A. E., Veselov, M. S., Chufarova, N. V., Chernyaginab, E. S., Vanzcool, A. S., Zyk, N. V., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.09.070 · Cited by 53
Yu, B., Shi, X., Qi, P., Yu, D., & Liu, H. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.01.015 · Cited by 52
Potent oxindole based human β3 adrenergic receptor agonists
Stevens, F. C., Bloomquist, W. E., Borel, A. G., Cohen, M. L., Droste, C. A., Heiman, M. L., Kriauciunas, A., Sall, D. J., Tinsley, F. C., & Jesudason, C. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.011 · Cited by 49
Oost, T. K., Backfisch, G., Bhowmik, S., van Gaalen, M. M., Geneste, H., Hornberger, W., Lubisch, W., Netz, A., Unger, L., & Wernet, W. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.012 · Cited by 48
Synthesis of Potent Oxindole CDK2 Inhibitors
Dermatakis, A., Luk, K., & DePinto, W. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00036-1 · Cited by 48
Oxindole Derivatives: Synthesis and Antiglycation Activity
Khan, K., Khan, M., Ambreen, N., et al. (2013) · Medicinal Chemistry · doi:10.2174/1573406411309050007 · Cited by 44
Watanabe, H., Ono, M., Kimura, H., Matsumura, K., Yoshimura, M., Okamoto, Y., Ihara, M., Takahashi, R., & Saji, H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.086 · Cited by 43
Lladó, I., Estrany, M. E., Rodríguez, E., Amengual, B., Roca, P., & Palou, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801390 · Cited by 32
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors
Kim, M. H., Tsuhako, A. L., Co, E. W., Aftab, D. T., Bentzien, F., Chen, J., Cheng, W., Engst, S., Goon, L., Klein, R. R., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.029 · Cited by 31
Singh, S. B., Tiwari, K., Verma, P., Srivastava, M. P., Tiwari, K. P., & Singh, J. (2013) · Supramolecular chemistry · doi:10.1080/10610278.2012.761341 · Cited by 29
Fletcher, D. S., Candelore, M. R., Grujić, D., Lowell, B. B., Luell, S., Susulic, V. S., & MacIntyre, D. E. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37849-8 · Cited by 28
Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists
Guo, C., Pairish, M., Linton, A., Kephart, S. E., Ornelas, M. A., Nagata, A., Burke, B. J., Dong, L., Engebretsen, J., & Fanjul, A. N. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.116 · Cited by 24
Indolidan: A Potent, Long‐Acting Cardiotonic and Inhibitor of Type IV Cyclic AMP Phosphodiesterase
Kauffman, R. F., Robertson, D. W., Franklin, R. B., Sandusky, G. E., Díes, F., McNay, J. L., & HAYES, J. S. (1990) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.1990.tb00398.x · Cited by 24
Yasuda, D., Takahashi, K., Ohe, T., Nakamura, S., & Mashino, T. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.021 · Cited by 24
Hatakeyama, Y., Sakata, Y., Takakura, S., Manda, T., & Mutoh, S. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00131.2004 · Cited by 16
Clinical Uses of Mifepristone (MFP)
Ulmann, A., Peyron, R., & Silvestre, L. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb31382.x · Cited by 9
Cited by
An overview of spirooxindole as a promising scaffold for novel drug discovery
Zhou, L.-M., Qu, R.-Y., & Yang, G.-F. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1733526 · Cited by 316
Metadata
- Authors
- Kaur, M., Singh, M., Chadha, N., & Silakari, O.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 123
- Pages
- 858-894
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2511938130
- Cited by
- 349
- References
- 62
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.